Chemokine expression in experimental tubulointerstitial nephritis

W W Tang1, M Qi, J S Warren

  • 1Department of Pathology, Amgen Inc., Thousand Oaks, CA 91320, USA.

Insights

Monocyte chemotactic protein-1 (MCP-1) and interferon-inducible protein-10 (IP-10) chemokines are upregulated in puromycin aminonucleoside (PAN) nephrosis, driving leukocyte infiltration. Neutralizing MCP-1 significantly reduced macrophage infiltration in tubulointerstitial nephritis.

Area of Science:

  • Nephrology
  • Immunology
  • Molecular Biology

Background:

  • Tubulointerstitial nephritis is a key feature of glomerular disease.
  • Chemokines mediate leukocyte infiltration in inflammatory kidney diseases.

Purpose of the Study:

  • To investigate the role of specific chemokines in puromycin aminonucleoside (PAN) nephrosis-induced tubulointerstitial nephritis.
  • To determine the cellular source and temporal expression of chemokines during PAN nephrosis.

Main Methods:

  • Quantitative analysis of renal cortical chemokine mRNA expression (IP-10, MCP-1, RANTES, CINC, MIP-2, MIP-1alpha) at various time points post-PAN induction.
  • Localization of chemokine mRNA production using in situ hybridization.
  • Measurement of MCP-1 protein levels via ELISA.
  • Assessment of tubulointerstitial leukocyte infiltration (T lymphocytes, macrophages).
  • In vivo blockade of MCP-1 using a neutralizing antibody.

Main Results:

  • A significant, transient increase in renal cortical IP-10 and MCP-1 mRNA expression was observed 6-8 days after PAN administration.
  • IP-10 and MCP-1 mRNA were produced by intrinsic tubulointerstitial cells.
  • MCP-1 protein levels correlated with increased T lymphocyte and macrophage infiltration, peaking around day 10.
  • Neutralization of MCP-1 led to a 45% reduction in tubulointerstitial macrophage infiltration on day 6.

Conclusions:

  • MCP-1 is a critical chemokine involved in monocyte/macrophage recruitment in PAN nephrosis.
  • IP-10 may also play a role in the inflammatory process.
  • Targeting MCP-1 could be a therapeutic strategy for tubulointerstitial nephritis associated with glomerular disease.